Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Eli Lilly

Buy, Sell, or Hold? Insiders Pile Into These 3 Healthcare Stocks

Insiders are buying stocks like LLY, TFX, and CALC. The question is whether they are also a good buy for investors, and not all of them are.

MarketBeat

New Obesity Drugs May See Premium Pricing Undermined By Underwhelming Data

Eli Lilly and Co. (NYSE:LLY) and Novo Nordisk A/S (NYSE:NVO) are expected to launch new obesity-treatment pills in the U.S. next year at prices comparable to their existing injectable drugs, signaling a break from the industry trend of charging more for new therapies.

Benzinga

Like Eli Lilly, Viking Therapeutics' Oral Weight Loss Drug Disappoints, Stock Tanks

On Tuesday, Viking Therapeutics Inc. (NASDAQ:VKTX) released the much-awaited data from its Phase 2 trial of VK2735 pill, the company’s dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors.

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

2 Outstanding ‘Strong Buy’ Stocks to Grab in August

These two stocks offer a rare combination of income and growth.

Barchart

Ozempic price slashed following Donald Trump's demands - will it impact the UK cost?

Novo Nordisk said it has no plans to rise UK prices, despite pressure from Trump

Evening Standard

Weight loss drugs: how will you be affected by the Mounjaro price rise in the UK?

We’d like to hear from people who are taking Mounjaro and how they feel about the increase in cost for doses

The Guardian - UK

Eli Lilly Considering Viking Therapeutics Acquisition? Expert Says 'They're Setting Up For Something BIG' As LLY Issues 40-Year Bond

Eli Lilly And Co.‘s (NYSE:LLY) recent, and highly unusual, issuance of a 40-year bond is fueling speculation that the pharmaceutical giant may be preparing for a major acquisition, with Viking Therapeutics Inc. (NASDAQ:VKTX) emerging as a potential target.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Patients switch to Ozempic en masse as Mounjaro hikes prices

IN FULL

The Independent UK

Christopher Biggins latest celebrity to confirm he is using weight loss jabs

Actor and television personality Biggins, 76, is taking Eli Lilly jab Mounjaro

The Independent UK

Ozempic sales surge ‘up to 600%’ after Mounjaro price rises

Price hikes are 'kick in the teeth' for patients who will either have to swallow 170 per cent price increase, or switch to 'almost as good' competitor

The Independent UK

Ozempic Lawsuit: Patients Claim Life-Threatening Side Effects As Safety Questions Put Zepbound In The Spotlight

Over 2,000 Ozempic and Zepbound lawsuits allege life-threatening side effects as FDA updates warnings and courts weigh evidence.

International Business Times UK

Voices: Pricing people out of using Mounjaro would be bad news for the NHS

COMMENT: The astronomical rise in weight-loss drug prices caused by Trump’s tariffs could have a significant – and dangerous – impact on Britain’s pharmacies and patients, writes Leyla Hannbeck, CEO of the Independent Pharmacies Association

The Independent UK

Jim Cramer Says Don't Quit Market When It's Frothy: 'Is Widespread Irrationality a Reason To Sell Down in Perfectly Rational Stocks? Absolutely Not'

In the face of a frothy market, financial expert Jim Cramer encourages investors to stay the course, highlighting numerous positive stock narratives that counterbalance the market’s irrationality.

Benzinga

Novo Nordisk's Lead Fades, Eli Lilly Holds Course For Outsized Gains, Says Analyst

On Thursday, Eli Lilly and Co. (NYSE:LLY) said it will sharply increase the list price of its weight-loss and type 2 diabetes drug Mounjaro (tirzepatide) in the United Kingdom.

Benzinga

Get all your
news in one place.

100's of premium titles.
One news app.

International Business Times UK

Mounjaro Is About to Get More Expensive in the UK: Here Are Cheaper Alternatives Available Right Now

Mounjaro's UK price will rise by 170% in September, prompting interest in cheaper alternatives like semaglutide for weight loss.

International Business Times UK

Eli Lilly Mounjaro UK Price Increase Set To Soar By Up To 170%—Private Patients Facing £330 Monthly Costs

Eli Lilly will raise UK private prices for Mounjaro by up to 170 percent from September 2025, with the highest dose set to cost £330 monthly while NHS prices stay unchanged.

Benzinga

Eli Lilly Strikes $1.3 Billion Deal With Superluminal To Develop AI-Driven Obesity Drugs

Eli Lilly and Co (NYSE:LLY) has entered into a $1.3 billion deal with Superluminal Medicines to develop small-molecule drugs through artificial intelligence (AI) to treat obesity and other cardiometabolic diseases.

The Guardian - UK

Eli Lilly ramps up UK price of weight loss jab Mounjaro after Trump demands

The US president had put pressure on the pharmaceutical industry to make drugs cheaper for Americans

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Eli Lilly To Raise Mounjaro Price In UK, Expands Obesity Drug Push In India

Eli Lilly and Co. (NYSE:LLY) will sharply increase the list price of its weight-loss and type 2 diabetes drug Mounjaro (tirzepatide) in the United Kingdom, while expanding its market presence in India with a new injector pen.

Euronews

Eli Lilly hikes UK price of blockbuster weight loss drug Mounjaro by up to 170%

The price hike is not expected to affect access for patients who receive Mounjaro through the National Health Service (NHS).

Benzinga

Viking's Oral Obesity Drug Poised To Gain Ground After Eli Lilly's Orforglipron Setback: Analyst

Viking Therapeutics, Inc. (NASDAQ:VKTX) is pressing ahead in the weight-loss drug race with the launch of its Phase 2 VENTURE-Oral trial to test a daily pill version of VK2735 in obese and overweight adults, a move analysts say could position the company to capitalize on Eli Lilly’s recent setback and…

Benzinga

How Novo Nordisk's Weight-Loss Drug Could Unlock A Better Future For Biogen's Alzheimer's Treatment

Biogen Inc. (NASDAQ:BIIB) CEO Chris Viehbacher said a successful Alzheimer’s trial for Novo Nordisk A/S’ (NYSE:NVO) weight-loss drug wouldn’t threaten his company’s treatment but could instead open the door to combining therapies for stronger results.

Benzinga

Texas Sues Eli Lilly For Alleged Kickback Scheme Involving Mounjaro, Zepbound

Texas Attorney General Ken Paxton has filed a lawsuit against Eli Lilly and Co. (NYSE:LLY), accusing the pharmaceutical giant of bribing medical providers to promote its most profitable drugs, including the widely used GLP-1 medications Mounjaro and Zepbound for diabetes and weight loss.

Benzinga

UK Government, Eli Lilly Partner To Target Obesity Health Gaps

A new program to improve access to weight management services across the U.K. National Health Service (NHS) could benefit several obese patients.

Benzinga

Cramer Expects This FinTech To Reach $100, Upset With Eli Lilly: 'Come Back And Talk To Me'

On CNBC's “Mad Money Lightning Round,” Jim Cramer said Affirm Holdings Inc (NASDAQ:AFRM) is a buy. “It's at $72, it's going to $100,” he noted.

1 … 9 10 11 12

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Lawsuit

13,131 stories

Artificial Intelligence

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.